Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.

优化小分子力学模拟治疗与年龄相关的骨质疏松症。

基本信息

项目摘要

Abstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanosensor in osteoblasts in bone. Genetic ablation of PC1 and its downstream effector TAZ in osteoblasts results in defective osteoblast-mediated bone formation and increased bone marrow adipogenesis. Our premise is that the 1PC1+3PC2 complex in bone is a novel target for developing anabolic drugs to treat senile osteoporosis. Oak Ridge Therapeutic Discovery, LLC (ORRxD) is a drug discovery company focused on supercomputer driven structure-based small molecule hit discovery. Using structure-based drug design and extensive structure-activity relationship studies, we discovered a series of small lead molecules or “mechanomimetics” that bind to the coiled-coiled domain of 1PC1+3PC2 and selectively promote PC/1PC2 interactions to enhance calcium channel activity and TAZ signaling. These lead compounds stimulate osteoblast function and inhibit adipogenesis in vitro and stimulate osteoblast-mediated bone formation and inhibit bone marrow fat accumulation in vivo leading to increased bone mass. Patent protection for these molecules is being pursued by our academic partner, the University of Tennessee Research Foundation (UTRF). Our goal is to de-risk these novel chemical mechanomimetics. For Aim 1 we will scale up sufficient quantities to perform target binding assays, assess off-target effects, test their efficacy (EC50) to stimulate PC1/PC2 complex signaling in vitro and perform in vitro absorption, distribution, metabolism, and excretion (ADME), and in vitro toxicity studies. For Aim 2 we will perform in vivo maximum tolerated dose (MTD), pharmacokinetics (PK) and short-term efficacy studies in relevant pre-clinical mouse models. Our expected outcomes are to identify the single best compound meeting efficacy, ADME, PK, and safety properties to enter IND enabling studies in Phase II. ORRxD has the option to license these mechanomimetics from UTRF and will pursue a plan to commercialize these first-in-class drugs to treat senile osteoporosis in humans.
摘要 存在开发用于老年性骨质疏松症的治疗的未满足的需求,所述老年性骨质疏松症是一种以年龄相关的骨质疏松为特征的病症。 骨生成的相互减少和骨髓脂肪的增加。老年骨质疏松症类似废用 骨质减少,提示其发病机制涉及骨机械感知受损。我们发现 多囊蛋白异源三聚体复合物(1 PC 1 + 3 PC 2)在骨中的成骨细胞中起机械传感器的作用。遗传 成骨细胞中PC 1及其下游效应物TAZ的消融导致成骨细胞介导的骨缺损 形成和增加骨髓脂肪生成。我们的前提是,骨中的1 PC 1 + 3 PC 2复合物是一种 为开发治疗老年性骨质疏松症的合成代谢药物提供了新的靶点。橡树岭治疗发现有限责任公司 (ORRxD)是一家专注于超级计算机驱动的基于结构的小分子药物发现公司。 的发现利用基于结构的药物设计和广泛的构效关系研究,我们 发现了一系列小的先导分子或“机械模拟物”,它们结合到 1 PC 1 + 3 PC 2和选择性地促进PC/1 PC 2相互作用以增强钙通道活性和TAZ 信号这些先导化合物在体外刺激成骨细胞功能并抑制脂肪形成, 成骨细胞介导的骨形成和抑制体内骨髓脂肪积聚,导致骨增加 马萨诸塞州这些分子的专利保护正在由我们的学术合作伙伴, 田纳西研究基金会(UTRF)。我们的目标是降低这些新型化学机械模拟物的风险。为 目标1:我们将扩大足够的数量,以进行靶向结合试验,评估脱靶效应,测试其 功效(EC 50)刺激体外PC 1/PC 2复合信号传导并进行体外吸收、分布, 代谢和排泄(ADME)以及体外毒性研究。对于目标2,我们将进行体内最大值 相关临床前小鼠的耐受剂量(MTD)、药代动力学(PK)和短期疗效研究 模型我们的预期结果是确定满足疗效、ADME、PK和 安全特性,以进入IND II期研究。ORRxD可以选择许可这些 UTRF的机械模拟药,并将实施计划将这些一流的药物商业化以治疗老年人 人类的骨质疏松症

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

L DARRYL QUARLES其他文献

L DARRYL QUARLES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('L DARRYL QUARLES', 18)}}的其他基金

Polycystins/TAZ as a novel therapeutic target to treat osteoporosis
多囊蛋白/TAZ作为治疗骨质疏松症的新靶点
  • 批准号:
    10194039
  • 财政年份:
    2018
  • 资助金额:
    $ 24.97万
  • 项目类别:
Skeletal Functions of Polycystins and TAZ
多囊蛋白和 TAZ 的骨骼功能
  • 批准号:
    10188427
  • 财政年份:
    2018
  • 资助金额:
    $ 24.97万
  • 项目类别:
Skeletal Functions of Polycystins and TAZ
多囊蛋白和 TAZ 的骨骼功能
  • 批准号:
    9769623
  • 财政年份:
    2018
  • 资助金额:
    $ 24.97万
  • 项目类别:
Discovery of an Osteocalcin Sensing GPCR Regulating Beta-Cell Function
发现骨钙素感应 GPCR 调节 β 细胞功能
  • 批准号:
    8500840
  • 财政年份:
    2013
  • 资助金额:
    $ 24.97万
  • 项目类别:
Extrarenal Functions of Polycystin-1
Polycystin-1 的肾外功能
  • 批准号:
    7981005
  • 财政年份:
    2010
  • 资助金额:
    $ 24.97万
  • 项目类别:
Extrarenal Functions of Polycystin-1
Polycystin-1 的肾外功能
  • 批准号:
    8529506
  • 财政年份:
    2010
  • 资助金额:
    $ 24.97万
  • 项目类别:
Extrarenal Functions of Polycystin-1
Polycystin-1 的肾外功能
  • 批准号:
    8318217
  • 财政年份:
    2010
  • 资助金额:
    $ 24.97万
  • 项目类别:
Extrarenal Functions of Polycystin-1
Polycystin-1 的肾外功能
  • 批准号:
    8097524
  • 财政年份:
    2010
  • 资助金额:
    $ 24.97万
  • 项目类别:
Extrarenal Functions of Polycystin-1
Polycystin-1 的肾外功能
  • 批准号:
    8719976
  • 财政年份:
    2010
  • 资助金额:
    $ 24.97万
  • 项目类别:
University of Kansas Training Grant in Nephrology
堪萨斯大学肾病学培训补助金
  • 批准号:
    7485687
  • 财政年份:
    2006
  • 资助金额:
    $ 24.97万
  • 项目类别:

相似海外基金

Adipose tissue stem cells and its extracellular vesicles could attenuate acute lung injury in a newborn porcine model of respiratory distress and ventilatory induced lung injury.
脂肪组织干细胞及其细胞外囊泡可以减轻新生猪呼吸窘迫和通气引起的肺损伤模型中的急性肺损伤。
  • 批准号:
    22K07874
  • 财政年份:
    2022
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Acute and Chronic Effects of Adipose Tissue Growth on Cellular and Metabolic Processes
脂肪组织生长对细胞和代谢过程的急性和慢性影响
  • 批准号:
    418323-2012
  • 财政年份:
    2019
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Discovery Grants Program - Individual
Acute and Chronic Effects of Adipose Tissue Growth on Cellular and Metabolic Processes
脂肪组织生长对细胞和代谢过程的急性和慢性影响
  • 批准号:
    418323-2012
  • 财政年份:
    2018
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Discovery Grants Program - Individual
Acute and Chronic Effects of Adipose Tissue Growth on Cellular and Metabolic Processes
脂肪组织生长对细胞和代谢过程的急性和慢性影响
  • 批准号:
    418323-2012
  • 财政年份:
    2017
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Discovery Grants Program - Individual
Acute and Chronic Effects of Adipose Tissue Growth on Cellular and Metabolic Processes
脂肪组织生长对细胞和代谢过程的急性和慢性影响
  • 批准号:
    418323-2012
  • 财政年份:
    2016
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Discovery Grants Program - Individual
Acute and Chronic Effects of Adipose Tissue Growth on Cellular and Metabolic Processes
脂肪组织生长对细胞和代谢过程的急性和慢性影响
  • 批准号:
    418323-2012
  • 财政年份:
    2015
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Discovery Grants Program - Individual
Acute and Chronic Effects of Adipose Tissue Growth on Cellular and Metabolic Processes
脂肪组织生长对细胞和代谢过程的急性和慢性影响
  • 批准号:
    418323-2012
  • 财政年份:
    2014
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Discovery Grants Program - Individual
Acute and Chronic Effects of Adipose Tissue Growth on Cellular and Metabolic Processes
脂肪组织生长对细胞和代谢过程的急性和慢性影响
  • 批准号:
    418323-2012
  • 财政年份:
    2013
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Discovery Grants Program - Individual
Adipose Tissue-Derived Stem Cells Suppress Acute Cellular Rejection by TSG-6 and CD44 interaction in Rat Kidney Transplantation.
脂肪组织干细胞在大鼠肾移植中通过 TSG-6 和 CD44 相互作用抑制急性细胞排斥。
  • 批准号:
    25861419
  • 财政年份:
    2013
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Acute and Chronic Effects of Adipose Tissue Growth on Cellular and Metabolic Processes
脂肪组织生长对细胞和代谢过程的急性和慢性影响
  • 批准号:
    418323-2012
  • 财政年份:
    2012
  • 资助金额:
    $ 24.97万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了